{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:26:57Z","timestamp":1786706817498,"version":"build-2736575974"},"reference-count":36,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"publisher","award":["TSGH\u2010D\u2010114168"],"award-info":[{"award-number":["TSGH\u2010D\u2010114168"]}],"id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Epidermal growth factor receptor (EGFR) inhibitors, including tyrosine kinase inhibitors (TKIs), are associated with paronychia and pyogenic granuloma\u2013like lesions (PGLs) that significantly impair patients' quality of life. Topical beta\u2010blockers emerge as a non\u2010invasive and promising therapy for such adverse events. This meta\u2010analysis evaluated the efficacy of topical beta\u2010blockers for EGFR inhibitor\u2010induced paronychia and PGLs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>In accordance with the PRISMA 2020 guidelines, multiple databases were searched for relevant studies. The primary outcomes were overall response rate (ORR) and complete response rate (CRR) within 1\u2009month. Secondary outcomes included safety outcomes and subgroup analyses, while meta\u2010regression was performed to assess the moderating effects of baseline characteristics. R programming was used for analysis and plotting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Six studies involving 96 patients were included. Topical beta\u2010blocker yielded a high pooled ORR of 0.94 (confidence interval, CI 0.81\u20131.00,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200969%) and CRR of 0.34 (CI 0.15\u20130.57,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200976%) within 1 month. Despite no significant between\u2010group differences, lower CRR were found in lung cancer (0.35, 95% CI [0.12, 0.60]) and solution formation subgroup (0.30, 95% CI [0.06, 0.62]). Meta\u2010regression identified negative trends in CRRs for female patients and TKI users (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.1). No adverse event was reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our research concluded that topical beta\u2010blockers may be a well\u2010tolerated and beneficial option for managing EGFR inhibitor\u2010induced paronychia and PGL. Additional and large\u2010scale randomized controlled trials are necessary to confirm these findings, standardize treatment protocols, and evaluate long\u2010term effectiveness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71476","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T06:36:57Z","timestamp":1769495817000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of Topical Beta\u2010Blockers in Managing Epidermal Growth Factor Receptor Inhibitor\u2010Related Paronychia and Pyogenic Granuloma\u2010Like Lesion: A Systematic Review and Meta\u2010Analysis"],"prefix":"10.1002","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9771-674X","authenticated-orcid":false,"given":"Po\u2010Kai","family":"Chan","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Tri\u2010Service General Hospital National Defense Medical University  Taipei City Taiwan (ROC)"},{"name":"School of Medicine, College of Medicine, National Defense Medical Universatiy  Taipei City Taiwan (ROC)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei\u2010Ting","family":"Yen","sequence":"additional","affiliation":[{"name":"School of Medicine, College of Medicine, National Defense Medical Universatiy  Taipei City Taiwan (ROC)"},{"name":"Department of Ophthalmology, Tri\u2010Service General Hospital National Defense Medical University  Taipei City Taiwan (ROC)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po\u2010Huang","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Tri\u2010Service General Hospital National Defense Medical University  Taipei City Taiwan (ROC)"},{"name":"School of Medicine, College of Medicine, National Defense Medical Universatiy  Taipei City Taiwan (ROC)"},{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Tri\u2010Service General Hospital National Defense Medical University  Taipei City Taiwan (ROC)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.10.009"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.06.009"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.001"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-019-1278-9"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000020510"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14674"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.010"},{"issue":"2","key":"e_1_2_13_9_1","article-title":"Topical \u03b2\u2010Blockers for the Management of Paronychia and Pyogenic Granulomalike Lesions of the Periungual Area Secondary to Therapy With Epidermal Growth Factor Receptor Inhibitor","volume":"12","author":"Sollena P.","year":"2020","journal-title":"Journal of the Dermatology Nurses' Association"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04690-8"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.01.015"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.06.040"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2017-110853"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14730"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212613"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.4120"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221122051"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.14075"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1970"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.804212"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/351210"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13671-024-00421-3"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000012"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M601007200"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2008.09.013"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.21984"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph15020110"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15740"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.005"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2024.07.029"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15099"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0253139"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx702"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.13167"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1159\/000490177"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.1.110"},{"key":"e_1_2_13_37_1","unstructured":"NCT \u201cEfficacy and Safety of Timolol for TKI Induced Paronychia \u201d2023 https:\/\/clinicaltrialsgov\/ct2\/show\/NCT06140186."}],"updated-by":[{"DOI":"10.1002\/cam4.71647","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000}},{"DOI":"10.1002\/cam4.72156","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000}}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71476","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.71476","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71476","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:28:20Z","timestamp":1786703300000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/cam4.71476"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71476","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"assertion":[{"value":"2025-05-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71476"}}